Pre-made CAR Negative Control Lentivirus express the Anti-CD19 CAR construct of “anti-CD19-ScFV (VL-VH)-CD8 hinge-CD28”, containing Puromycin (Puro) selection. It has the entire ANti-CD19 CAR construct except the CD3ζ activation domain, thus serving as the negative control to validate the specificity of the Anti-CD19 (CD28) CAR-T targeted killing. The lentivector’s core structure is represented by the scheme below. see details in Product Manual.
CD19 is a marker of in most B cell leukemias and lymphomas but not in any normal tissue other than the B cell lineage, CD19 is used to diagnose cancers that arise from this type of cell, and is used as the target for CD19-targeted therapies.
CD28 is transmembrane protein expressed on T cells. It provides co-stimulatory signals for inducing T cell activation and proliferation. CD28 is widely used as the costimulatory domain in CARs.
Amount: 200 ul/vial at titer of 1×108 IFU/ml, concentrated lentivirus provided in PBS solution, premixed with 10x polybrene (60ug/ml), premade, ready to ship, in dry-ice package.